Sunil Kumar/LinkedIn
Dec 17, 2025, 23:37
Sunil Kumar: Top 10 Drugs Driving Revenue in Rare Disease Therapeutics (2024)
Sunil Kumar, Entrepreneur of Medifit Devices LLP, shared a post on LinkedIn:
“Top 10 Drugs Driving Revenue in Rare Disease Therapeutics (2024).
Rare diseases may affect smaller patient populations, but strong science, high unmet need, and long term therapy adoption continue to translate into meaningful revenues. From enzyme replacement therapies to advanced coagulation factors, these products underline the commercial strength of rare disease portfolios.
The list highlights reported 2024 revenues along with primary approved indications across areas such as amyloidosis, hemophilia, and inherited metabolic disorders.”
Stay updated with Hemostasis Today.
-
Apr 15, 2026, 15:33Peter Zdziarski: Will Glanzmann Thrombasthenia Patients Be Formally Recognized as Benefiting from SevenFACT?
-
Apr 15, 2026, 15:20Sonal Sonu: Blood Donation Myths in Rural Areas
-
Apr 15, 2026, 15:01Augustina Isioma Ikusemoro: The Most Misunderstood Cause of a Prolonged APTT in the Laboratory
-
Apr 15, 2026, 14:55Donald Correll: Key Risk Factors for Venous Thromboembolism
-
Apr 15, 2026, 14:48Fadwa Said Abdelazim: Is Vaping Really ‘Safer’ for the Blood Than Smoking?
-
Apr 15, 2026, 14:42Augustina Isioma Ikusemoro: An Underrecognized Cause of Severe Thrombocytopenia Following Transfusion
-
Apr 15, 2026, 14:42Caitlin Raymond: Augmented Intelligence Enhancing Human Capability Without Replacement
-
Apr 15, 2026, 14:39Pooja Choradia: Recognizing Pulmonary Embolism in Pregnancy Before It Is Too Late
-
Apr 15, 2026, 14:38Alessandra Bosch։ Understanding Haemostasis in Children and Its Challenges